Public, NASDAQ:VICL
NASDAQ Global Market
Vical signs LOI with AnGes for pandemic influenza program
Date: Wed, 08 Oct 2008 14:10:22 GMT
Tags:
Vical signs LOI with AnGes for pandemic influenza program
Trading Markets (press release) - Oct 8, 2008
Trading Markets (press release) - Oct 8, 2008
Oct 08 , 2008 ( Datamonitor via COMTEX ) - - VICL | Quote | Chart | News | PowerRating - - Vical , a developer of biopharmaceutical products , and AnGes MG , a biopharmaceutical company , have ...
Vical Inc executes letter of intent with AnGes MG Inc for pandemic influenza vaccines - Trading Markets (press release)Vical says Vaxfectin adjuvant to be utilized in Infectious Disease and Cancer vaccines - Update
Date: Wed, 08 Oct 2008 12:04:27 GMT
Tags:
Vical says Vaxfectin adjuvant to be utilized in Infectious Disease and Cancer vaccines - Update
RTT News - Oct 8, 2008
RTT News - Oct 8, 2008
( RTTNews ) - Wednesday , Bio - pharmaceutical company , Vical Inc . ( VICL : News ) said expanded clinical data and new non - clinical data showed that its Vaxfectin adjuvant could be broadly ...
Vical Expands Applications of Vaxfectin Adjuvant for Infectious Disease and Cancer Vaccines - quick facts - RTT NewsVical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Date: Wed, 08 Oct 2008 10:42:42 GMT
Tags:
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
MarketWatch - Oct 8, 2008
MarketWatch - Oct 8, 2008
, , ) today is presenting expanded clinical data and new nonclinical data demonstrating that the company's Vaxfectin ( R ) adjuvant may be broadly applicable in DNA - and protein - based infectious ...
Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
Date: Tue, 07 Oct 2008 21:46:32 GMT
Tags:
Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
PipelineReview.com (press release) - Oct 7, 2008
PipelineReview.com (press release) - Oct 7, 2008
SAN DIEGO , CA , USA | October 7 , 2008 | Vical Incorporated ( Nasdaq : VICL ) and AnGes MG , Inc . , have signed a non - binding Letter of Intent indicating their mutual interest to license ...
Market Report -- In Play (WIRES)
Date: Tue, 07 Oct 2008 11:21:15 GMT
Tags:
Market Report -- In Play (WIRES)
MSN Money - Oct 7, 2008
MSN Money - Oct 7, 2008
On The Wires Vical ( VICL ) and AnGes have signed a non - binding Letter of Intent indicating their mutual interest to license the development and marketing rights for Vical's pandemic influenza ...
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months (PR Newswire)
Date: Wed, 8 Oct 2008 10:30:00 Etc/GMT
Tags:
Vical Incorporated today is presenting expanded clinical data and new nonclinical data demonstrating that the company's Vaxfectin® adjuvant may be broadly applicable in DNA- and protein-based infectious disease vaccines and peptide-based cancer vaccines.
Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program (PR Newswire)
Date: Tue, 7 Oct 2008 10:30:00 Etc/GMT
Tags:
Vical Incorporated and AnGes MG, Inc., have signed a non-binding Letter of Intent indicating their mutual interest to license the development and marketing rights for Vical's pandemic influenza DNA vaccines in Japan to AnGes.
Vical to Present at UBS Global Life Sciences Conference (PR Newswire)
Date: Mon, 15 Sep 2008 10:30:00 Etc/GMT
Tags:
The Vical Incorporated presentation at the UBS Global Life Sciences Conference on Monday, September 22, at 1 p.m. Eastern Daylight Time, will be available by live and archived webcast through the Events page at http://www.vical.com.
Vaxfectin(R)-formulated Measles DNA Vaccine Could Address Unmet Need for Infants (PR Newswire)
Date: Thu, 21 Aug 2008 10:30:00 Etc/GMT
Tags:
Vical Incorporated today announced that results from nonhuman primate studies of a Vaxfectin®-formulated DNA vaccine for measles, published in the August issue of Clinical and Vaccine Immunology, offer a promising approach to the development of a measles vaccine to address an unmet need for human infants.
Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control (PR Newswire)
Date: Tue, 19 Aug 2008 10:30:00 Etc/GMT
Tags:
Vical Incorporated today announced a research collaboration with the Karolinska Institute, a leading European medical university, and the Swedish Institute for Infectious Disease Control , a governmental expert agency, to evaluate Vical's Vaxfectin® adjuvant with the Biojector® 2000 needle-free injection system for a multivalent preventive DNA vaccine against HIV.